phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

AskAboutAdherence_Header-1Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study on the savings associated with new hepatitis C treatments.

A new study in the American Journal of Managed Care found that, by 2022, a total of 331,967 Medicaid enrollees are estimated to have been cured of the hepatitis C virus (HCV), leading to an estimated total savings to Medicaid of $12 billion, net of treatment costs, from avoided health care costs.

The Medicaid population has a high prevalence of HCV, a disease associated with expensive complications such as cirrhosis and liver cancer. But highly effective interferon-free Direct-Acting Antivirals (DAAs), first approved in 2013, can cure this disease, and avoid the substantial health care costs associated with HCV and its complications. For example, on an individual basis, a patient cured of HCV can expect to fully offset costs of DAA treatment after only 16 months.

By 2017, annual cost savings associated with curing the disease are estimated to have exceeded treatment costs to Medicaid. Year after year, as more patients in Medicaid are cured and savings continue to grow, the total cost of DAAs since the introduction of these treatments are fully offset by the total savings achieved through reduction in health care costs. By 2022, the cumulative amount of these savings is estimated to reach $12 billion dollars.

Projecting these findings out further, another analysis estimated the cumulative amount of these savings to Medicaid, net of DAA costs, will reach $52.7 billion by 2028.

HEP C Graph FINAL

Partnership for Health Analytic Research, LLC. Analysis based on results reported in Roebuck M, Liberman J. Burden of Illness of Chronic Hepatitis C in Medicaid. Am J Manag Care. 2019; 25:-S0

To learn more about how medicines are often the most cost-effective means of preventing and treating disease, visit www.letstalkaboutcost.org.

Katie Koziara

Katie Koziara is Senior Director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.

Katie Koziara

New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid

May 25, 2023

New data show how insurers and middlemen shift Rx costs onto patients

November 16, 2022

Sharing rebates can save Americans with diabetes 500 each year and improve adherence

March 16, 2022

CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018

October 19, 2021

Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022

Adherence

Ask About Adherence

Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022

June 21, 2019

Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list